Charles River Labs Stock - Morgan Stanley upgrade shifts sentiment

Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 16:10 CET. Details in the imprint.

Charles River Labs (US1591881009) draws fresh analyst attention this week after Morgan Stanley upgraded the stock to Overweight and raised its price target to $220, citing a more attractive risk-reward setup as biopharma funding improves, according to an Investing.com summary of the Morgan Stanley note.

Morgan Stanley backs Charles River

Morgan Stanley now prefers Charles River over CRO peer IQVIA in a sector reset, pointing to improving biotech funding and portfolio changes that favor Charles River’s earnings trajectory, according to the analyst note summarized by Investing.com.

The bank lifted its price target to $220, a level it equates with roughly 14 times its 2026 EBITDA estimate for the company, signaling increased confidence in the medium-term profit outlook for the contract research business.

Wednesday focus - operations and strategy

Charles River’s business is highly leveraged to global biopharma R&D budgets, and the analyst upgrade explicitly links the company’s prospects to a gradual recovery in biotech funding after a softer 2022-2023 period for early-stage capital, as highlighted in the additional Morgan Stanley coverage summary.

Strategically, the broker points to Charles River’s diversified portfolio of discovery, safety assessment and manufacturing services as a key advantage in capturing outsourcing demand across the drug development value chain, especially as clients look for integrated CRO partners.

How the company makes money

Charles River Laboratories International, Inc. generates revenue mainly by providing preclinical and clinical laboratory services for drug discovery and development, including in vivo safety assessment studies, bioanalytical testing and related support for pharmaceutical and biotechnology customers worldwide.

Where the stock trades today

Charles River Labs (US1591881009) shares trade on the New York Stock Exchange at $184.79 as of 06/17/2026, 15:50 ET.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.